Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

The artificial intelligence company hopes to achieve success similar to Palantir's.

Huntington Ingalls Industries (HII) reports $3.1B Q2 revenue, backlog at $56.9B, with enhanced free cash flow guidance.

Segment operating income2 in the second quarter of 2025 was $172 million and segment operating margin2 was 5.6%, compared to $203 million and 6.8%, respectively, in the second quarter of 2024. The ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...